RefleXion Medical announced that it closed an $80 million equity financing to support its therapeutic oncology technology.
Hayward, California-based RefleXion develops biology-guided radiotherapy (BgRT) for all stages of cancer. The company designed BgRT to transform an injected radiotracer into a unified motion management solution that overcomes the technical limitations currently restricting radiotherapy use to one or two tumors.
BgRT recently received FDA breakthrough device designation for use in lung tumors, according to a news release. RefleXion plans to scale BgRT to treat all visible cancer sites, creating a new treatment option for patients with metastatic disease.
New investors joining the $80 million round were Ascension Ventures, Catalio Capital Management, Sixty Degree Capital and Hillenbrand Capital Partners.
Those new investors joined existing investors TPG’s The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridg…